Flashpoint Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Flashpoint Therapeutics - overview
Established
2022
Location
Redwood City, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2022, Flashpoint Therapeutics, Inc. , operates as a biotechnology platform that develops nanotherapeutics used to deliver immune stimulatory molecules with nanoscale architecture and optimized activation kinetics. In October 2023, Flashpoint Therapeutics, Inc. , raised USD 10 million in seed funding led by Beta Lab, with participation from CS Venture.
As of 2023, the company is led by its CEO, Adam Margolin. The company offers nanotechnology-enabled curative therapeutic solutions capable of delivering RNA, DNA, and peptide payloads to specific cells. The company’s platform allows for combinations of therapeutic components and optimizes structure-function relationships and activation kinetics. The company plans to use the October 2023 funding to increase the size of its team and improve its platform to create cutting-edge multi-targeted RNA, CRISPR, and peptide therapeutics.
Current Investors
CS Venture, Beta Lab
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.flashpoint.bio
Verticals
Nanotechnology
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Flashpoint Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.